Thermo Fisher Scientific Launches Wastewater Isolation Kit for SARS-CoV-2 Surveillance

Thermo Fisher Scientific Launches Wastewater Isolation Kit for SARS-CoV-2 Surveillance CARLSBAD, Calif., Oct. 5, 2021 /PRNewswire/ — Since the emergence of SARS-CoV-2, public health laboratories and researchers have been developing surveillance methods using wastewater to control the spread of COVID-19. The effort has helped identify asymptomatic carriers on college campuses to monitor regional spread among communities... Read more

Xylem, Dragos Partner to Bring Cybersecurity Leadership to Water Utilities

RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 4, 2021– Leading global water technology company, Xylem Inc., and Dragos, Inc., the global leader in cybersecurity for industrial controls systems (ICS)/operational technology (OT) environments, today announced they have partnered to bring best-in-class industrial cybersecurity to critical infrastructure in the water sector. The agreement will see Xylem and Dragos offering co-branded... Read more

Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology

Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology CARLSBAD, Calif., Sept. 29, 2021 /PRNewswire/ — To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for... Read more

Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses WALTHAM, Mass., Sept. 29, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc., (NYSE:TMO) the world leader in serving science, today announced continuing support for The Just Project, a national initiative to provide COVID-19 testing to students, faculty and staff across more than... Read more

Goldman Sachs, Xylem Launch First ESG-linked Demand Deposit Account

NEW YORK & RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 20, 2021– Goldman Sachs Transaction Banking Services has launched a new ESG (Environmental, Social and Governance) linked demand deposit account, with global water technology company, Xylem (NYSE:XYL), as its anchor client, the two companies announced today. The new Goldman Sachs Transaction Banking (TxB) product links the yield clients... Read more

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda’s Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations Oncomine Dx Target Test now approved as CDx for five targeted NSCLC therapies in the U.S. CARLSBAD, Calif., Sept. 15, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher... Read more

Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing

Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing New capacity will help U.S. customers meet current and future demand surges for vital laboratory plastics WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract... Read more

FDA Approves NGS-Based Companion Diagnostic for Previously Treated IDH1-Mutated Cholangiocarcinoma

FDA Approves NGS-Based Companion Diagnostic for Previously Treated IDH1-Mutated Cholangiocarcinoma CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for TIBSOVO CARLSBAD, Calif., Aug. 25, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted pre-market approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to... Read more

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1 Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy. Roche/GSK collaboration... Read more